Shares of microcap oncology company Tempest Therapeutics Inc. (TPST) plunged more than 50% on Thursday, following a remarkable 40-fold gain in the previous day. The surge in trading prompted a temporary halt due to volatility. This significant increase in stock value was triggered by the release of new study results for Tempest's investigational treatment, TPST-1120, for liver … [Read more...] about Tempest Therapeutics Stock Drops Over 50% After Rapid Surge
Footer
